Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Casirivimab/imdevimab - Regeneron Pharmaceuticals/Roche

Drug Profile

Casirivimab/imdevimab - Regeneron Pharmaceuticals/Roche

Alternative Names: Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies - Regeneron Pharmaceuticals/Roche; Casirivimab and Imdevimab - Regeneron Pharmaceuticals/Roche; Casirivimab+Imdevimab - Regeneron Pharmaceuticals/Roche; REGEN-COV; REGEN-COV2; REGEN-COVTM; REGN COV2; REGN-10933+ REGN-10987; REGN10933-10987; RG 6413/RG 6412; Ronapreve; SARS-CoV-2 virus multi-antibody therapy - Regeneron Pharmaceuticals/Roche

Latest Information Update: 20 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Chugai Pharmaceutical; Regeneron Pharmaceuticals; Roche
  • Class Antibodies; Antivirals; Monoclonal antibodies
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 14 Sep 2021 Regeneron enter Purchase agreement with the US Government agreement for the purchase of additional doses of casirivimab/imdevimab
  • 31 Aug 2021 Regeneron Pharmaceuticals completes a phase I/II/III trial in COVID-2019 infections in USA, Brazil, Mexico, Chile, Romania, Moldova (IV) in June 2021 (NCT04426695) (EudraCT2020-002537-15)
  • 23 Aug 2021 Roche plans to submit Provisional registration to Therapeutics Goods Administration for COVID-2019 infections
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top